Aprea Therapeutics (APRE) Earnings Analysis
Aprea Therapeutics (APRE) has no confirmed upcoming earnings date. Last quarter (2026-03-16) it beat with EPS -0.32 USD vs -0.38 USD est (+15.8%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -0.38.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does APRE next report earnings?
No confirmed upcoming earnings date is currently scheduled for APRE. This page updates as the calendar is published.
APRE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-16 | -0.32 USD | -0.38 USD | +15.8% | Beat |
| 2025-08-12 | -0.53 USD | -0.77 USD | +31.2% | Beat |
| 2024-08-12 | -0.58 USD | -0.64 USD | +9.4% | Beat |
Beat rate: 3/3 (100%) over reported quarters with consensus data.
APRE valuation and analyst view
| Trailing P/E | -0.38 |
|---|---|
| Trailing EPS | -1.55501 USD |
| Price / book | 0.12 |
| Dividend yield | 0.00% |
| Market cap | 0.00B |
| Analyst consensus | Buy (4 buy / 2 hold / 2 sell) |
Related research pages
Frequently asked questions
When is Aprea Therapeutics (APRE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for APRE. This page updates as the calendar is published.
Did APRE beat earnings last quarter?
In its 2026-03-16 report, APRE posted EPS of -0.32 USD versus a -0.38 USD estimate — a beat of 15.8%.
What is APRE's earnings track record?
Over the last 3 reported quarters with consensus data, APRE beat estimates 3 times (100%).
What is APRE's current P/E ratio and EPS?
APRE trades at a trailing P/E of -0.38 on trailing EPS of -1.5550061973519376 USD.
What do analysts rate APRE?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 4 buy, 2 hold, 2 sell, 0 strong sell).